Mr. Givi Topchishvili to Join Innocan Pharma’s Advisory Committee

0
22

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – November 18, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan’s Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Givi Topchishvili will join the advisory team to support Innocan’s goals to expand its distribution and licensing activities in the US.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2022/11/mr-givi-topchishvili-to-join-innocan-pharmas-advisory-committee.jpg?w=696&ssl=1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6922/144763_af8ac63244a2da9d_002full.jpg

About Mr. Givi Topchishvili

Givi Topchishvili is a serial entrepreneur, investor, and author, with 30 years of expertise in business development and market entry in Europe, Asia, and the US. He has founded and led to a successful exit multiple companies in the media, IT, healthcare, business advisory and marketing space. He has extensive experience in business performance transformation, venture capital, due diligence and post-merger integration aligned with emerging markets strategy.

Givi Topchishvili follows the key principle of building trustworthy partnerships and he is always focused on the understanding of a client’s business challenges and goals on multiple levels. He has created efficient roadmaps leading companies to a transformational change, corporate development, building effective product and channel strategies, and in certain cases, executing successful M&A and post-merger integrations. As a published author, he wrote a number of books on business strategy, including “Marketing in the New Millennium – Models for Success” and “The Science of Winning in Investments, Management, and Marketing.” Holds a Ph.D. in Physical Chemistry and is active in a number of charitable organizations and business societies.

“We are very excited to have Mr. Givi Topchishvili join our Advisory Committee here at Innocan Pharma”. said CEO Iris Bincovich, “He is a great addition to Innocan’s Advisory Committee and adds a unique perspective, given his accomplished business career”.

About Innocan

Innocan is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation. In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales. www.innocanpharma.com

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

15162104025+
+972-54-3012842
+442037699377
[email protected]

Dr. Eva Reuter
Investment Relation- Germany
+46-69-1532-5857
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144763

LEAVE A REPLY

Please enter your comment!
Please enter your name here